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Background: Heterogeneously distributed hypoxic areas are a characteristic property of locally advanced breast
cancers (BCa) and generally associated with therapeutic resistance, metastases, and poor patient survival. About
50% of locally advanced BCa, where radiotherapy is less effective are suggested to be due to hypoxic regions. In
this study, we investigated the potential of bioactive phytochemicals in radio-sensitizing hypoxic BCa cells.
Methods: Hypoxic (O2-2.5%; N2-92.5%; CO2-5%) MCF-7 cells were exposed to 4 Gy radiation (IR) alone or after
pretreatment with Curcumin (CUR), curcumin analog EF24, neem leaf extract (NLE), Genistein (GEN), Resveratrol
(RES) or raspberry extract (RSE). The cells were examined for inhibition of NFκB activity, transcriptional modulation
of 88 NFκB signaling pathway genes, activation and cellular localization of radio-responsive NFκB related mediators,
eNos, Erk1/2, SOD2, Akt1/2/3, p50, p65, pIκBα, TNFα, Birc-1, -2, -5 and associated induction of cell death.
Results: EMSA revealed that cells exposed to phytochemicals showed complete suppression of IR-induced NFκB.
Relatively, cells exposed EF24 revealed a robust inhibition of IR-induced NFκB. QPCR profiling showed induced
expression of 53 NFκB signaling pathway genes after IR. Conversely, 53, 50, 53, 53, 53 and 53 of IR-induced genes
were inhibited with EF24, NLE, CUR, GEN, RES and RSE respectively. In addition, 25, 29, 24, 16, 11 and 21 of
35 IR-suppressed genes were further inhibited with EF24, NLE, CUR, GEN, RES and RSE respectively. Immunoblotting
revealed a significant attenuating effect of IR-modulated radio-responsive eNos, Erk1/2, SOD2, Akt1/2/3, p50, p65,
pIκBα, TNFα, Birc-1, -2 and −5 with EF24, NLE, CUR, GEN, RES or RSE. Annexin V-FITC staining showed a
consistent and significant induction of IR-induced cell death with these phytochemicals. Notably, EF24 robustly
conferred IR-induced cell death.
Conclusions: Together, these data identifies the potential hypoxic cell radio-sensitizers and further implies that
the induced radio-sensitization may be exerted by selectively targeting IR-induced NFκB signaling.
Keywords: Breast cancer, Hypoxia, Radio-sensitization, Phytochemicals, NFκB, Curcumin, EF24, Neem leaf extract,
Genistein, Resveratrol, Raspberry extractBackground
Radiotherapy (RT) remains one of the prime treatment
modality for breast cancer. It was established mainly in
the 1990s that a low pre-treatment intra-tumoral partial
oxygen pressure (pO2), as determined by needle elec-
trode measurement, is associated with a poor outcome
of treatment, in particular RT but also surgical treatment* Correspondence: naravind@ouhsc.edu
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reproduction in any medium, provided the orof several tumor types [1,2]. This association has been
explained by the reduced ability of ionizing radiation
(IR) to produce DNA damage in the absence of oxygen
as well as, more recently, by an increased potential of
hypoxic tumor cells for proliferation, invasion, metasta-
sis and angiogenesis [3]. Consistently, studies have de-
termined that poor tumor oxygenation is the strongest
prognostic indicator of radiotherapy treatment outcome
[4-6] and have indicated that breast tumor pO2 distri-
bution prior to radiotherapy is sufficient to predict local
response [7].tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and oxygen consumption resulting in the reduction of
oxygen tension below the normal level for a specific tis-
sue [8], is a common feature of most solid tumors includ-
ing breast carcinoma. This is partly due to the abnormal
vascularization in tumors, which is insufficient in supply-
ing O2 to the sometimes rapidly expanding malignant le-
sions. The use of polarographic O2 needle electrodes
have revealed low pO2 values of 23–28 mmHg (median)
for tumors, as opposed to benign lesions (42 mmHg) and
normal tissue (54–65 mmHg) [9,10]. Particularly, of all
readings taken from breast cancers, 30–40% falls below
10 mmHg, which is very rarely seen in normal tissue
[9,10]. Further, studies have revealed that nearly 40% of
breast malignancies exhibit tumor regions with oxygen
concentrations below that required for half-maximal
radio-sensitivity (pO2 < 2.5 mmHg) [9]. To that end, for
decades, investigators have attempted to overcome the
treatment resistance of hypoxic tumors in clinical trials,
for example by adding so-called 'hypoxic radio-sensitizer'
drugs to the regimens or introducing hyperbaric oxygen.
Although many of the individual trials were negative, a
modern meta-analysis confirms the efficacy of hypoxia-
directed treatments [11]. Consequently, recent research
focusing on hypoxic responses and delineation of import-
ant regulators of hypoxia has clearly indicated that ‘the
hypoxia response’ in tumors can be used to define novel
treatment strategies [8]. The future arsenal of novel can-
cer therapies will most certainly include specific targeting
of hypoxic process.
The presence and extent of the hypoxic tumor micro-
environments have recently been shown to influence
tumor progression by regulating both tumor cell survival
and the expression of key angiogenic molecules. To that
end, numerous studies have implicated the transcription
factor, NFκB as a mediator of the hypoxic processes in
tumor cells [12,13]. On the other hand, we and others
have demonstrated a pronounced activation of NFκB in
response to IR in tumor cells including breast cancer
cells [14-17]. NFκB is a member of the c-rel proto-
oncogene family found within the promoter and enhan-
cer region of a wide variety of cellular genes involved in
proliferation, differentiation and cell cycle control
[18,19]. Unlike other inducible transcription factors, a
multitude of conditions and agents, including IR, can ac-
tivate NFκB in cells. On activation, NFκB can stimulate
various targeted late-response genes [18,19], including
those responsible for cell cycle control, oncogenic activa-
tion, [20], cell growth, differentiation and metastasis
[21,22]. More importantly, studies have established the
influence of NFκB in induced adaptive resistance, inflam-
matory and proliferation response [23-26]. Together with
the fact that NFκB is able to regulate >150 genes, hypoxia
induced NFκB signal transduction and activity may play akey role in transcriptional activation of these downstream
targets that potentially regulate radio-sensitization.
A plethora of recent research has been focused on
exploiting the pharmacologically safe, bioactive phyto-
chemicals as potent radio-sensitizers in a number of
tumor types including breast cancer. To that note, we
have shown that nutraceuticals viz., curcumin (CUR),
black raspberry extract (RSE), neem leaf extract (NLE)
etc., regulate a number of potential molecular targets
and potentiate radio-sensitization in neuroblastoma,
pancreatic cancer and breast tumor systems [15,27-31].
Here in, we investigated the effects of CUR, curcumin
analog EF24, NLE, Genistein (GEN), Resveratrol (RES)
and RSE on the NFκB DNA-binding activity and NFκB
signal transduction in hypoxic breast cancer cells ex-
posed to IR. Furthermore, we elucxidated the effects of
these bioactives in the activation and cellular localization
of hypoxia-responsive NFκB related effectors including
p53, Akt, Nos3, Erk1/2, SOD2, p50, p65, TNFα, IAP1,
IAP2 and Survivin. More importantly, we elucidated the
efficacy of these compounds in potentiating IR induced
hypoxic cell killing in this setting. In hypoxic breast cancer
cells, CUR, EF24, NLE, GEN, RES and RSE resulted in the
(i) complete suppression of IR-induced NFκB-DNA bind-
ing activity (ii) attenuation of IR-induced NFκB signal
transduction and target transcriptome, (iii) mitigation of
IR-induced Akt,, Nos3, Erk1/2, SOD2, p50, p65, TNFα,
Birc 1, 2 and 5 and (iv) potentiates IR-induced cell killing,
implying that these bioactive phytochemicals may play a
key role in regulating NFκB signaling pathway dependent
‘hypoxic processes’ and may potentiate RT in this setting.
Methods
Cell culture
Estrogen receptor positive human adenocarcinoma
(MCF-7) breast cancer cells were maintained as mono-
layer cultures by weekly serial passage in 100 mm tissue
culture plates in Dulbecco’s Modified Eagle medium
(Cellgro, Herndon, VA) with 44 mM sodium bi-carbonate,
4 mM L-glutamine, supplemented with 10.2 IU/ml penicil-
lin/10.2 mg/ml streptomycin, and 10% heat-inactivated
fetal bovine serum (Atlanta Biological, Lawrence Ville,
GA). When in exponential growth, the cells were observed
to have a doubling time of approximately 16–18 h. For
passage and for all experiments, the cells were detached
using trypsin (0.25%)/EDTA (1%), re-suspended in
complete medium, counted electronically using Countess
Cell counter (Life Technologies Corp.) and incubated in a
95% air/5% CO2 humidified incubator.
Hypoxia, phytochemicals treatment and Irradiation
experiments
The cells plated in 100 mm tissue culture plates containing
6 ml of complete growth medium were allowed to grow up
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by serum starvation overnight followed by treatment. For
growth under hypoxia, the cells were incubated at 37°C in
a modular chamber flushed with 2.5% O2, 5% CO2 and
92.5% N2. For phytochemical studies, 2.0μg/ml RSE
[27,31], 100nM CUR [15,29,31], 0.1% NLE [30,31], 200nM
EF24 [32], 100 μM GEN and 100 μM RES was added to
the medium for 1 h before hypoxia. For IR experiments,
the cells were irradiated with one single high dose
(SDR-4 Gy) using Gamma Cell 40 Exactor (Nordion
International Inc, Ontario, Canada) at a dose rate of
0.81 Gy/min. Mock irradiated cells were treated identical
except that the cells were not subjected to IR. The experi-
ments were repeated at least three times in each group. In
all the groups the cells were harvested 24 h after IR.
Electrophoretic mobility shift assay
Nuclear protein extraction and electrophoretic mobility
shift assay for NFκB, were performed as described in our
earlier studies [33]. Autoradiograms were overexposed to
portrait the inhibitory effect below constitutive level.
Densitometry analysis was performed using a BioRad
Multi-Analyst software package with an integrated density
program. Group-wise comparisons were made using
ANOVA with Tukey’s post-hoc correction. A P value of
<0.05 is considered statistically significant. For the compe-
tition assay, the nuclear extract was pre-incubated with un-
labeled homologous NFκB oligonucleotide followed by
addition of [γ-32P]-ATP labeled NFκB probe. Super shift
analysis was performed as described earlier [33].
Real-Time QPCR profiling of NFκB signaling pathway
molecules
Total RNA extraction and real-time QPCR profiling
were performed as described in our earlier studies
[33,34]. We used human NFκB signaling pathway
profiler (Realtimeprimers.com, Elkins Park, PA)
containing 88 genes representing 8 functional groups
including (i) Rel/NFκB/IκB family, (ii) NFκB respon-
sive genes, (iii) Ligands & Transmembrane receptors,
(iv) Adaptor proteins, (v) Signal transduction kinases,
(vi) Transcription factors, (vii) Cell death/survival
molecules, and (viii) Other factors. We started with
this highly selected QPCR profiler instead of an all-
encompassing gene array because the selected genes entail
a well-characterized profile governing NFκB signal trans-
duction and transcriptional targets, hence facilitating inter-
pretation of data, simplifying data acquisition and analysis,
and avoiding genes not functionally characterized. Further-
more, QPCR profiling allows detection and quantifica-
tion of gene expression in real-time. Each profiling plate
was also equipped with reverse transcription control,
positive PCR control, genomic DNA control and five
housekeeping genes – β-Actin, GAPDH, Rpl13a, HPRT1and β2M. The ΔΔct values were calculated by normaliz-
ing the gene expression levels to the expression of the
housekeeping genes. The normalized data were then com-
pared between groups, and the relative expression level of
each gene was expressed as fold change.
Immunoblotting
Total protein extraction and immunoblotting were
performed as described in our earlier studies [33]. Rabbit
polyclonal anti-Birc1, 2, 5, eNOS, SOD2, AKT1/2/3,
TNFα, p53, pAKT1/2/3 (all obtained from Santa Cruz
Biotechnology Inc., Santa Cruz, CA), p50, p65 (obtained
from Abcam, Cambridge, MA), ERK1/2 (Cell Signaling
Technology, Danvers, MA), mouse monoclonal anti-
pERK1/2 (Cell Signaling), pIκBα (Santa Cruz) and, goat
polyclonal anti-peNOS (Santa Cruz) antibodies were
used to detect the respective protein expression and
phosphorylation levels in response to hypoxia and IR in
conjunction with different phytochemicals. Blots were
stripped and reprobed with mouse monoclonal anti-
α-tubulin antibody (Santa Cruz) to determine equal load-
ing of the samples. 1D gel analysis was performed using a
BioRad Multi-Analyst software package with an integrated
density program. Group-wise comparisons were made
using ANOVA with Tukey’s post-hoc correction. A P value
of <0.05 is considered as statistically significant.
Annexin-V binding assay
The apoptotic events was quantified by the binding of
Annexin-V to the externalized protein, phosphatidylserine,
on the cell membrane during apoptosis with the
ApoScreen Annexin V-Fluorescein (FITC) Kit (Southern
Biotech, Birmingham, AL), according to the manufacturer’s
instructions. Briefly, the floating and trypsinized-adherent
of hypoxic and untreated cells with or without IR and/or
phytochemicals were collected and washed with PBS. Cells
were resuspended in 1X binding buffer to a concentration
of 1x107 cells/ml were then stained with 10 μL of Annexin
V-FITC and 5 μl of propidium iodide (50 μg/ml) for
15 min on ice, protected from light. Cells were analyzed
using FACS Calibur flow cytometer equipped with a
488 nm argon laser and gated on viable cells by light scat-
ter. Group-wise comparisons were made using ANOVA
with Tukey’s post-hoc correction. A P value of <0.05 is
considered as statistically significant.
Results
Nutraceuticals impede IR-induced p50/p65 expression
and DNA-binding activity in hypoxic BCa cells
To delineate the effect of IR on NFκB expression and
DNA-binding activity in hypoxic breast cancer cells and
further to elucidate the efficacy of nutraceuticals in this set-
ting, human BCa (MCF-7) cells cultured under hypoxic
conditions were either mock-irradiated or exposed to IR
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RSE pre-treatment and harvested after 24 h post-IR. Com-
pared to cells grown under normoxia, EMSA revealed a
significant induction (300.3±71.6%) of NFκB-DNA binding
activity in hypoxic BCa cells (Figure 1A). Further, exposure
of hypoxic cells to IR resulted in a robust (813.7±216.5) in-
duction of NFκB DNA-binding activity. On the other hand,
we observed a consistent and complete inhibition of this
IR-induced DNA-binding activity in EF24 (6.2±4.0%),
NLE (52.5±11.3%), CUR (24.4±4.9%), GEN (43.8±9.1),















































































Figure 1 (A) A representative autoradiogram showing NFκB DNA-bi
radiation with or without EF24, NLE, CUR, GEN, RES or RSE pre-treatmen
labeled NFκB-specific probe. Compared to the normoxia controls, hypoxi
IR-exposure further enhanced hypoxia induced NFκB activity. Hypoxic ce
significant inhibition of IR-induced NFκB-DNA binding activity. (B) Semi-q
CUR, GEN, RES or RSE on IR-induced NFκB-DNA binding activity in hypo
IκBα phosphorylation, nuclear translocation of NFκB p50 and p65 in hyp
RES or RSE treatment. Total cell extracts for pIκBα and nuclear extracts fo
validate equal sample loading. (D) Histograms of densitometric analysis n
IR-induced IκBα phosphorylation and nuclear translocation of p50/p65 in
Group-wise comparisons were made using two-way ANOVA with Tukey’sMCF-7 cells. More importantly, an assiduous inhibitory
potential of these nutraceuticals was evident with NFκB-
DNA binding levels lesser than that of normoxic-mock-IR
cells (Figure 1B). Consistently, western blot analysis from
the nuclear extract revealed a significant induction of
NFκB p50 and p65 levels in hypoxic BCa cells (Figure 1C).
This hypoxia induced nuclear translocation of p50 and p65
is further enhanced with IR-exposure. More importantly,
EF24, NLE, CUR, GEN, RES and RSE significantly reverted
the IR-induced p50/p65 nuclear translocation in this set-
ting (Figure 1C & D). On the other hand, we observed anxia IR GEN CUR NLE EF24 RES RSE
0.001
 ‡  ‡  ‡  ‡  ‡  ‡  ‡
‡ Compared to Normoxia-Mock-IR Control
IR (4Gy)
Hypoxia (O2 = 2.5%)
nding activity levels in MCF-7 cells exposed to hypoxia and/or
t. The nuclear extracts were analyzed by EMSA using γ-32p [ATP]
c cells showed a significant induction of NFκB-DNA binding activity.
lls treated with EF24, NLE, CUR, GEN, RES or RSE showed a
uantitative densitometric analysis showing the effect of EF24, NLE,
xic MCF-7 cells. (C) Western blot analysis showing modulation in the
oxic MCF-7 cells exposed to IR with or without EF24, NLE, CUR, GEN,
r p50 and p65 were used.α-tubulin expression was determined to
ormalized to α-tubulin expression showing complete inhibition of
hypoxic BCa cells with EF24, NLE, CUR, GEN, RES or RSE treatment.
post-hoc correction.
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hypoxic conditions, which was further enhanced when the
cells were exposed to IR (Figure 1D). However, a consistent
inhibition of IκBα phosphorylation in hypoxic cells pre-
treated with EF24, NLE, CUR, GEN, RES or RSE and ex-
posed to IR was evident (Figure 1D). These results corre-
lated well with the NFκB data which together validates the
regulation of NFκB in response to hypoxia and radiation
with or without nutraceuticals.
Nutraceuticals targets NFκB signaling transcriptome in
hypoxic breast cancer cells
Further to substantiate that bioactive nutraceuticals
intervene IR-induced NFκB signaling in hypoxic cells,
MCF-7 cells cultured under hypoxic conditions were ei-
ther mock-irradiated or exposed to IR (2 Gy) with or
without EF24, NLE, CUR, GEN, RES and RSE pre-Figure 2 Histograms showing attenuation and/or complete suppressi
EF24, NLE, GEN, RES or RSE treatment in hypoxic human breast aden
signaling pathway profiler (Realtimeprimers.com, Elkins Park, PA) containing
normalizing the gene expression levels to the expression of the housekeep
change.treatment and harvested after 3 h post-IR. Custom
QPCR profiling of 88 NFκB upstream/downstream sig-
nal transduction pathway molecules revealed that clinic-
ally relevant doses of radiation significantly induced 53
genes (Figure 2) and suppressed another 35 genes in
hypoxic breast cancer cells. To that end, IR robustly in-
creased the transcription of NFκB family molecules in-
cluding Rel, RelA, RelB, IKKβ and IKKγ and, serves as
the positive controls for the study. Interestingly, pres-
ence of nutraceuticals in the system completely and
comprehensively reverted this IR-induced NFκB signal
transduction in hypoxic cells. Treatment with EF24,
CUR, GEN, RES and RSE resulted in complete suppres-
sion of all 53 IR-induced NFκB signal transduction genes
in these cells under hypoxic conditions. NLE reverted 50
of 53 IR-induced genes in this setting (Figure 2). Evi-
dently, all the nutraceuticals investigated revealed aon of 59 IR-induced NFκB signaling pathway genes with CUR,
ocarcinoma cells. QPCR profiling was performed using human NFκB
88 genes and 8 internal controls. The ΔΔct values calculated by
ing genes were compared between groups and expressed as fold
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cules. Altogether, 50 of 53 IR-induced NFκB signaling
pathway genes were targeted in common with EF24,
NLE, CUR, GEN, RES and RSE. Conversely, IR-exposure
resulted in the inhibition of 35 NFκB signaling pathway
genes as opposed to hypoxia alone. Notably, EF24, NLE,
CUR, GEN, RES and RSE treatment further conferred
25, 29, 24, 16, 11 and 21 of those IR-suppressed genes.
Of these, five genes including Csf1, NFκB2, PPM1A,
RAF1 and RHOA were commonly conferred after all
nutraceuticals investigated.
Nutraceuticals reverts IR-altered cellular localization and/
or activation of NFκB signaling pathway proteins in
hypoxic breast cancer cells
To confirm further that the bioactive EF24, NLE,
CUR, GEN, RES and RSE targeted NFκB signaling
pathway transcriptome is in fact translated into the
NFκB signal transduction, we examined the alterations
in both the cellular levels and activation of certain se-
lect NFκB upstream (AKT, ERK, eNOS), downstream













































































Figure 3 (A) Western blot analysis showing modulation in TNFα, Birc 1, 2
ERK1/2 in hypoxic MCF-7 cells exposed to IR with or without EF24, NLE,
to validate equal sample loading. (B) Histograms of densitometric analysis norm
and IR-induced TNFα, Birc 1, 2, 5, SOD2, and phosphorylation of eNOS, AKT1/2/
treatment. Group-wise comparisons were made using two-way ANOVA with Ttransduction/effector proteins (Figure 3A). Compared
to normoxic conditions, TNFα and SOD2 immunoblot-
ting revealed a profound increase (P<0.001) in hypoxia
treated cells. This hypoxia induced induction of both
TNFα and SOD2 was significantly enhanced when the
cells were exposed to IR (Figures 3A & B). However,
pretreating the cells either with EF24, NLE, CUR, GEN,
RES or RSE completely (P<0.001) knock down this hyp-
oxia and/or IR-activated TNFα and SOD2 in human
MCF-7 cells (Figure 3B). Consistently, we observed an
impetuous increase in NFκB direct downstream targets
including Birc 1, 2 and 5 in cells exposed to hypoxia. Ra-
diation on the other hand, significantly reduced the ex-
pression of these Bircs in the hypoxic cells. Nevertheless,
EF24, NLE, CUR, GEN, RES or RSE treatment in con-
junction with IR completely (P<0.001) knocked down
these NFκB dependent pro-survival Birc 1, 2 and 5 in
hypoxic cells (Figures 3A & B). Analyzing the expres-
sion and phosphorylation of NFκB upstream signal
transducing AKT, ERK and eNOS conform our tran-
scriptome profiling data. Interestingly, induced expres-
sion levels of AKT1/2/3 in response to hypoxia and, 5, SOD2, constitutive and phosphorylation of eNOS, AKT1/2/3 and
CUR, GEN, RES or RSE treatment. α-tubulin expression was determined
alized to α-tubulin expression showing complete inhibition of hypoxia
3 and ERK1/2 in hypoxic BCa cells with EF24, NLE, CUR, GEN, RES or RSE
ukey’s post-hoc correction.
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In parallel, hypoxia in the system instigated a robust
(>4 fold) phosphorylation of AKT1/2/3. Notably, this
hypoxia induced AKT1/2/3 phosphorylation was fur-
ther (P<0.001) influenced with IR-exposure. More im-
portantly, EF24, NLE, CUR, RES or RSE completely
mute both the IR-induced cellular levels and phos-
phorylation of AKT1/2/3 in the hypoxic cells
(Figures 3A & B). GEN on the other hand showed ei-
ther no effect or increase in the cellular expression of
AKT1/2/3. However, consistent with other bioactives,
we observed a significant inhibition of IR-induced
AKT1/2/3 phosphorylation in these hypoxic cells. Fur-
thermore, hypoxia resulted in the relative increase in
the constitutive eNOS and significant increase in the
phosphorylation of eNOS. Interestingly, we did not see
any further increase in eNOS phosphorylation with IR
exposure. Conversely, EF24, NLE, CUR, GEN, RES or
RSE treatment resulted in complete suppression of the
hypoxia and/or IR altered eNOS phosphorylation
(Figures 3A & B). In addition, we observed a signifi-
cant and robust increase in the ERK1/2 phosphoryl-
ation after hypoxia. Radiation evidently influenced
further phosphorylation of ERK1/2 in these hypoxic
cells. Consistent with the AKT and eNOS phosphoryl-
ation muting observed, we observed a total inhibition
of ERK1/2 phosphorylation in EF24, NLE, CUR, GEN,
RES or RSE treated cells (Figures 3A & B).
EF24, NLE, CUR, GEN, RES and RSE confers IR-induced cell
death in hypoxic breast cancer cells
To determine whether the bioactives targeting NFκB sig-
naling cascade is in fact translates to functional response
and to elucidate the radio-potentiating effect of these
drugs in hypoxic conditions, we examined the alterations
in induced cell death in hypoxic cells exposed to IR with
or without EF24, NLE, CUR, GEN, RES or RSE treatment
(Figure 4A & B). Opposed to mock-IR hypoxic cells, IR
exposure significantly induced (P<0.01) cell death in cells
under hypoxia. However, coherent with our NFκB data,
this IR-induced cell death is profoundly influenced in
cells treated with EF24, NLE, CUR, GEN, RES or RSE
(Figure 4B). Relatively, novel synthetic monoketone of
curcumin, EF24 instigate more radiopotentiating effect
as evident with the robust (P<0.001) cell death.
Discussion
Radiotherapy is very effective in local control of cancer-
ous tumors, but its curative potential is often limited by
intrinsic radio-resistance of the tumor cells. Hypoxia is
one such limiting factor and indeed a main factor in
most tumors including breast cancer that affects the
radio-therapeutic ratio. Tumors tend to outgrow their
blood supplies and develop hypoxic regions thatpreferentially protect tumor cells from radiation-induced
DNA damage, as oxygen not only fixates DNA damage
but also increases the number and complexity of DNA
lesions produced by radiation. It has been shown that
hypoxia can alter the biological state of tumor cells, in-
cluding the transcription and translation of various pro-
teins involved in cell survival [35]. Variety of metabolic
stress signals including hypoxia activates NFκB [13,36],
that rapidly transduce hypoxic signals and facilitates the
rapid control of many genes. Mechanisms involved in
hypoxia induced NFκB is discussed in detailed elsewhere
[37]. Since hypoxia can induce NFκB activation, this
pathway may contribute to a pro-malignant phenotype
not only by promoting cell proliferation and survival,
but also by upregulating gene products that control
cell adhesion and angiogenesis. To that note, though a
number of studies have identified the possible role of
NFκB dependent downstream response in hypoxic pro-
cesses, a definitive insight on the regulation of NFκB
signaling in response to hypoxia in breast cancer, if not
in any tumors is still at vague. Moreover, how this hyp-
oxia associated NFκB response translates after any prime
therapeutic intervention is not understood. To our
knowledge, this is the first attempt to characterize NFκB
signaling in hypoxic breast cancer cells in response to a
treatment modality, here in this case, radiotherapy and,
further to delineate the modulation of altered signaling
response to known anti-tumor phytochemicals. Consist-
ent with the published evidence [13,36,38], hypoxia
resulted in significant induction of NFκB activity and
serves as the positive controls for the study. In addition,
the results also add on a new insight on the altered
NFκB signaling pathway transcriptome modulation in re-
sponse to hypoxia in these cells. However, for the first
time, this study identified that the radiation instigated
pronounced NFκB activation and its signal transduction
in surviving hypoxic breast cancer cells. Both from our
laboratory and studies from other investigators demon-
strated that clinical radiotherapy resulted in predominant
activation of NFκB in surviving tumor cells including
breast cancer cells [15-17,27-29,31,33,39]. The results
presented here portraits that radiation robustly increased
nuclear translocation and DNA binding activity of NFκB,
transactivation of 53 NFκB family, signaling and effector
molecules and further resulted in activation of TNFα,
AKT1/2/3, SOD2 and ERK1/2 at least in surviving hyp-
oxic breast cancer cells. A plethora of evidence has
demonstrated that both AKT and ERK are upstream of
NFκB and are actively involved in NFκB activation.
Like-wise, we have demonstrated that TNFα and SOD2
though are the direct downstream targets of NFκB sig-
naling are in fact individually exerts a positive feedback
input with NFκB signaling that promotes robust and
persistent NFκB activation after radiation [33,34].
Figure 4 (A) FACS analysis showing annexin V-FITC staining (with ApoScreen Annexin V-Fluorescein) in cells under normoxic and
hypoxic conditions exposed to IR with or without EF24, NLE, CUR, GEN, RES or RSE treatment. (B) Histograms showing significant increase
in cell killing with IR exposure in hypoxic cells and further radiopotentiating effect of bioactive EF24, NLE, CUR, GEN, RES or RSE in human breast
adenocarcinoma (MCF-7) cells exposed to hypoxia. Group-wise comparisons were made using ANOVA with Tukey’s post-hoc correction.
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standing of how the known bioactive phytochemicals
NLE, CUR, GEN, RES or RSE and synthetic analogue
(EF24, in this case) radio-sensitize and/or radio-
potentiate hypoxic breast cancer cells. The results pre-
cisely demonstrated that phytochemicals including neem
leaf extract, genistein, resveratrol, raspberry extract,
curcumin and, its synthetic analogue EF24 have signifi-
cant impact on attenuating radiation modulated NFκB
nuclear import, DNA-binding activity, signaling pathway
transcriptome and on the translational activation of its
signaling (TNFα, AKT1/2/3, SOD2 and ERK1/2) and ef-
fector (Birc 1, 2, 5) proteins in surviving hypoxic breast
cancer cells. To that end, the significant reverting effect
(53 off 53 except NLE where it is 50/53) IR-induced
transcriptional response demonstrate for the fact all
these compounds converge on the NFκB signaling path-
way to inhibit hypoxia induced radio-adaptation and to
radio-potentiate cell killing. A simplified schematic path-
way map is presented in Figure 5 in an attempt togive a glimpse of NFκB signaling targeted by these
compounds. CUR, a dietary polyphenol derived from
turmeric, Curcuma longa, is a pharmacologically safe
and effective agent that has been demonstrated to have
anti-inflammatory, antiproliferative, and antitumor ef-
fects by modulating many potential molecular targets
(47). Because of its use as a food additive and its potential
for cancer chemoprevention, curcumin has undergone
extensive toxicological screening and pre-clinical investi-
gation in rats, mice, dogs, and monkeys (48). Curcumin
has been demonstrated to inhibit NFκB by suppressing
the activation of IKK by interacting directly with the kin-
ase (47). Similarly, RES, a phytoalexin present in grape
skins and red wines, exerts striking inhibitory effects on
diverse cellular events associated with tumor initiation,
promotion, and progression [40]. A number of studies
showed RES associated inhibition of NFκB and further
have dissected out that it exerts the response through
(a) phosphorylation/degradation of IκBα via IKK [41];
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Figure 5 Schematic illustration of phytochemicals targeting NFkB signaling pathway. Curcumin, EF24, Resveratrol and Genistein targets
more than one signal transduction molecules in NFkB pathway and comprehensively affect NFkB dependent tumor progression.
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the most abundant isoflavone found in soybeans, is be-
lieved to be a potent anticancer agent [44,45] and is
currently under 34 (7 studies still open) clinical trials
(www.clinicaltrials.gov). Notably, NFκB inhibitory effect
[46-55] radio-sensitizing effects [55-62] of Genistein
have been well documented. To that end, Sarkar and
colleagues suggested that Genistein inhibited MEKK1
kinase activity may be responsible for the decreased
phosphorylation of IκBα and thereby result in the inacti-
vation of NFκB [63-66]. Furthermore, synthetic analogue
of curcumin, EF24 has shown to possess potent antican-
cer activity, both in vitro as well as in vivo [67]. More im-
portantly, EF24 has been shown to directly inhibit IKKβ
kinase activity [68]. In addition, we have recently shown
that bioactive RSE and NLE selectively target radiation
induced NFκB in surviving cancer cells and potentiate ra-
diation induced cell death [27,30,31].In the context of the breast cancer cure, research
around the globe is primarily and appropriately focused
on dissecting out the potential benefit of bioactive phy-
tochemicals. Indeed, half of the top anticancer drugs in
the USA are derived directly or indirectly from natural
products [69,70]. To that end, we and others have shown
that CUR, NLE, RSE, RES, GEN possess potent anti-
breast cancer properties by modulating many potential
molecular targets and thereby exerts breast cancer cell
killing, prevent tumor growth, invasion and metastasis
[27]. Interestingly, studies have shown that at least in
part, the benefits of these phytochemicals are imparted
by selectively targeting NFκB in breast cancer cells
[71-75]. However, as discussed above, hypoxia is a fre-
quent phenomenon in breast cancer, orchestrated as a
result of tumor outgrowing the existing vasculature lead-
ing to an adaptive response. Radiation as one of the
prime treatment modality for breast cancer, hypoxia
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cancer. Our result in the present study has shown that
the cellular response of hypoxia is modulated by the ubi-
quitous transcription factor NFκB. Besides the fact that
hypoxia affects general radio-sensitization processes
such as apoptosis and proliferation, our data linked hyp-
oxia associated NFκB activation to the radio-protective
phenotype in breast cancer cells. Exquisitely, the data
presented here demonstrated the potential of CUR,
EF24, NLE, RSE, RES and GEN in targeting not only
radiation-induced NFκB activation but also NFκB signal
transduction and downstream NFκB dependent transla-
tional/functional response. Though a lot need to be ex-
plored on response initiation signaling and molecular
mechanism(s) upstream of NFκB by these phytochemi-
cals, this study, per se ostensibly identified that
curcumin, its analogue EF24, genistein, resveratrol, rasp-
berry extract and neem leaf extract converge on selective
inhibition of NFκB signaling and thereby potentiates
radiotherapy in hypoxic breast cancer cells. Further
studies delineating the drug and radiation dose, func-
tional downstream molecular (effector) orchestration,
pre-clinical efficacy with appropriate animal models,
multi-compound combinatorial synergism, if any, are
warranted and are currently pursued in our laboratory.
Conclusions
In this study, we investigated the effects of CUR,
curcumin analog EF24, NLE, GEN, RES and RSE on the
NFκB DNA-binding activity and NFκB signal transduc-
tion in hypoxic breast cancer cells exposed to IR. Fur-
thermore, we elucidated the effects of these bioactives in
the activation and cellular localization of hypoxia-
responsive NFκB related effectors including p53, Akt,
Nos3, Erk1/2, SOD2, p50, p65, TNFα, IAP1, IAP2 and
Survivin. More importantly, we elucidated the efficacy of
these compounds in potentiating IR induced hypoxic cell
killing in this setting. In hypoxic breast cancer cells,
CUR, EF24, NLE, GEN, RES and RSE resulted in a (i) a
complete suppression of IR-induced NFκB-DNA binding
activity (ii) attenuation of IR-induced NFκB signal trans-
duction and target transcriptome, (iii) mitigation of IR-
induced Akt,, Nos3, Erk1/2, SOD2, p50, p65, TNFα, Birc
1, 2 and 5 and (iv) potentiates IR-induced cell killing,
implying that these bioactive phytochemicals may play
a key role in regulating NFκB signaling pathway
dependent ‘hypoxic processes’ and may potentiate R T
in this setting.
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